(VIANEWS) - PennyMac Mortgage Investment Trust (PMT), Fortress Biotech (FBIOP), New York Mortgage Trust (NYMTM) have the highest dividend yield stocks on this list.
| Rank | Financial Asset | Price | Change | Forward Dividend Yield | Updated (EST) |
|---|---|---|---|---|---|
| 1 | PennyMac Mortgage Investment Trust (PMT) | 12.56 | -4.49% | 11.99% | 2022-12-28 23:15:08 |
| 2 | Fortress Biotech (FBIOP) | 19.49 | 1.4% | 11.94% | 2022-12-20 19:12:22 |
| 3 | New York Mortgage Trust (NYMTM) | 19.25 | -1.64% | 9.97% | 2022-12-22 21:11:09 |
| 4 | Lumen Technologies (LUMN) | 5.20 | -1.79% | 8.63% | 2022-12-30 15:52:07 |
| 5 | Automatic Data Processing (ADP) | 238.57 | -0.85% | 2.08% | 2022-12-30 15:53:39 |
Close to 2K companies listed in the Nasdaq and NYSE pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. PennyMac Mortgage Investment Trust (PMT) - Dividend Yield: 11.99%
PennyMac Mortgage Investment Trust's last close was $12.56, 32.73% under its 52-week high of $18.67.
PennyMac Mortgage Investment Trust, a specialty finance company, invests primarily in mortgage-related assets in the United States. The company operates through Credit Sensitive Strategies, Interest Rate Sensitive Strategies, and Correspondent Production segments. Its Credit Sensitive Strategies segment invests in credit risk transfer (CRT) agreements, including firm commitment to purchase CRT securities, distressed loans, real estate, and non-agency subordinated bonds. The company's Interest Rate Sensitive Strategies segment engages in investing in mortgage servicing rights, excess servicing spreads, and agency and senior non-agency MBS; and related interest rate hedging activities. Its Correspondent Production segment engages in purchasing, pooling, and reselling newly originated prime credit residential loans directly or in the form of mortgage-backed securities (MBS). PNMAC Capital Management, LLC acts as the manager of PennyMac Mortgage Investment Trust. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its shareholders. PennyMac Mortgage Investment Trust was founded in 2009 and is headquartered in Westlake Village, California.
Earnings Per Share
As for profitability, PennyMac Mortgage Investment Trust has a trailing twelve months EPS of $-0.73.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.22%.Sales Growth
PennyMac Mortgage Investment Trust's sales growth is 109.7% for the present quarter and 28.1% for the next.
Annual Top and Bottom Value
At 02:15 EST PennyMac Mortgage Investment Trust stock was valued at $12.56, which is less than its 52 week high of $18.67 but higher than its low 52-week of $10.78.
Dividend Yield
Morningstar, Inc. claims that the next dividend payment will be on December 28, 2022. The forward dividend rate and forward dividend yield are estimated at 1.6.
Moving Average
PennyMac Mortgage Investment Trust's worth is way under its 50-day moving average of $14.03 and way below its 200-day moving average of $14.67.More news about PennyMac Mortgage Investment Trust.
2. Fortress Biotech (FBIOP) - Dividend Yield: 11.94%
Fortress Biotech's last close was $19.49, 26.31% below its 52-week high of $26.45.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.
Earnings Per Share
As for profitability, Fortress Biotech has a trailing twelve months EPS of $-0.86.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -143.38%.Moving Average
Fortress Biotech is currently at $19.84 per day, and $20.14 for 200 days.Volume
Today's last reported volume for Fortress Biotech is 6314 which is 25.56% below its average volume of 8482.
More news about Fortress Biotech.
3. New York Mortgage Trust (NYMTM) - Dividend Yield: 9.97%
New York Mortgage Trust's last close was $19.25, 25.79% under its 52-week high of $25.94.
New York Mortgage Trust, Inc. manages, acquires, finances, and invests in single-family and multifamily mortgage assets. The company's investments are residential loans, second mortgages and business purpose loans. It also invests in structured multifamily property investments such as preferred equity and mezzanine loan to multi-family owners. For federal income tax purposes, the company is a real-estate investment trust. If it pays at least 90% of its income to stockholders, the company would generally not be subject to federal corporate income tax. It was established in New York in 2003.
Earnings Per Share
As for profitability, New York Mortgage Trust has a trailing twelve months EPS of $0.05.
PE Ratio
New York Mortgage Trust has a trailing twelve months price to earnings ratio of 409.57. Meaning, the purchaser of the share is investing $409.57 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -12.09%.Volatility
New York Mortgage Trust's last week, last month's, and last quarter's current intraday variation average was a negative 0.19%, a positive 0.45%, and a positive 1.66%.
New York Mortgage Trust's highest amplitude of average volatility was 0.19% (last week), 1.25% (last month), and 1.66% (last quarter).
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Dec 28, 2022, the estimated forward annual dividend rate is 1.97 and the estimated forward annual dividend yield is 9.97%.
Annual Top and Bottom Value
New York Mortgage Trust stock was valued at $19.25 as of 02:15 EST. This is way lower than its 52-week peak of $25.94, and far higher than its 52 week low of $16.51.
Moving Average
New York Mortgage Trust's worth is under its 50-day moving average of $19.32 and way under its 200-day moving average of $21.51.More news about New York Mortgage Trust.
4. Lumen Technologies (LUMN) - Dividend Yield: 8.63%
Lumen Technologies's last close was $5.22, 65.45% below its 52-week high of $15.11.
Lumen Technologies, Inc. is a technology-focused communications and technology company that provides integrated products and services to residential and business customers across the United States. It operates in two markets: Mass Markets and Business. The company offers cloud and application services such as colocation and server services, managed security services and content delivery services. It also provides IP and data services including Ethernet, VPN, Internet Protocol (IP) and voice over the internet protocol. It also offers fiber infrastructure services, which include high-bandwidth optical wavelength networks and unlit optic fiber. It also offers voice and other services. This includes private line services that are specifically designed to connect two or more organizations; traditional time division multiplexing voice service portfolios; and synchronous optical network based Ethernet and legacy data hosting. The company had approximately 4.5million broadband subscribers as of December 31, 2021. The former name of the company was CenturyLink, Inc., but it changed its name in September 2020 to Lumen Technologies, Inc. Lumen Technologies, Inc. is located in Monroe, Louisiana.
Earnings Per Share
As for profitability, Lumen Technologies has a trailing twelve months EPS of $-0.71.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.68%.Yearly Top and Bottom Value
Lumen Technologies's stock is valued at $5.20 at 02:15 EST, way below its 52-week low of $9.31.
Volatility
Lumen Technologies's intraday variation average for the week and quarter ended last week was negative at 1.49%, negative at 0.40% and positive at 2.76%.
Lumen Technologies had the highest average volatility amplitude at 2.25%, 2.03% and 2.76 (last week), respectively.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.4%, now sitting on 19.69B for the twelve trailing months.
More news about Lumen Technologies.
5. Automatic Data Processing (ADP) - Dividend Yield: 2.08%
Automatic Data Processing's last close was $238.86, 13.12% below its 52-week high of $274.92.
Automatic Data Processing, Inc. provides cloud-based human capital management solutions worldwide. It operates in two segments, Employer Services and Professional Employer Organization (PEO). The Employer Services segment offers strategic, cloud-based platforms, and human resources (HR) outsourcing solutions. Its offerings include payroll, benefits administration, talent management, HR management, workforce management, insurance, retirement, and compliance services, as well as integrated HCM solutions. The PEO Services segment provides HR outsourcing solutions to small and mid-sized businesses through a co-employment model. This segment offers benefits package, protection and compliance, talent engagement, expertise, comprehensive outsourcing, and recruitment process outsourcing services. The company was founded in 1949 and is headquartered in Roseland, New Jersey.
Earnings per Share
Automatic Data Processing's trailing 12 months profit per share was $5.76.
PE Ratio
Automatic Data Processing's trailing 12 months earnings to price ratio is 41.45. The purchaser of the shares is therefore investing $41.45 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 76.38%.Moving Average
Automatic Data Processing's worth is below its 50-day moving average of $248.61 and above its 200-day moving average of $232.20.Earnings Before Interest, Taxes, Depreciation, and Amortization
Automatic Data Processing's EBITDA is 6.24.
Volume
Today's last reported volume for Automatic Data Processing is 496782 which is 70.45% below its average volume of 1681670.
More news about Automatic Data Processing.